Evidence map›Paper›PMID 33705258›Full record

ArticleHuman vaccines & immunotherapeutics2021

Nigerian media coverage of medical progress on the development of COVID-19 vaccine.

Chika Euphemia Asogwa

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Chika Euphemia AsogwaDepartment of Mass Communication, Federal University, Oye-Ekiti, Nigeria.ORCID 0000-0003-1246-7014

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a global shift in discource on issues related to COVID-19 with greater attention paid to the vaccine. COVID-19. Despite this, the literature on media coverage of COVID-19 is yet to be extended to media coverage of issues related to medical progress on a vaccine for the virus. The objective of the current study was to fill this gap by examining how Nigerian media report COVID-19 vaccine development In doing so, attention was paid to the frequency of coverage, sources of stories as well as story type used. Two newspapers and TV stations were sampled for the current study. The current study made use of content analysis with a code sheet as the instrument for data collection. The result of the current study revealed that only 23% of the media stories on COVID-19 were related to vaccine development. Additionally, most of the stories made use of official sources as well as straight news. Comparatively, newspapers covered more in vaccine development than TV. The implications of these results on medical communication and theory are discussed.

Indexed as

COVID-19Mass MediaCommunicationCOVID-19 VaccinesHumansNigeriaSARS-CoV-2COVID-19 VaccinesCoverageCOVID-19curenewspaperNigeriatreatmentTVvaccine

Identifiers

PMID33705258
PMCPMC8475581

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.